Retrospective Analysis for Patients With Metabolic Syndrome
NCT ID: NCT06182618
Last Updated: 2023-12-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
400 participants
OBSERVATIONAL
2023-06-01
2024-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Strategic Lifestyle Intervention for Metabolic Syndrome (SLIM-MET)
NCT06271200
Effect of a Low Glycemic Index on Metabolic Syndrome
NCT02356952
Metabolomics Predictors for Metabolic Disease Remission After Metabolic Syndrome Surgery.
NCT06645730
Metabolic Syndrome and Related Diseases in Healthcare Workers
NCT06543706
Intensive Lifestyle Intervention for Remission of Metabolic Syndrome
NCT04116905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
low-carbohydrate diet
20-30% carbohydrates, 40-45%fat, and 30-40%protein
dietary, semaglutide or/and metformin
patients were prescribed dietary and pharmaceuticals for weight loss
balanced diet
50-65% carbohydrate, 20-30% fat and 10-20% protein
dietary, semaglutide or/and metformin
patients were prescribed dietary and pharmaceuticals for weight loss
pharmacotherapy
semaglutide (1mg per week) or/and metformin (o.5g three times a day)
dietary, semaglutide or/and metformin
patients were prescribed dietary and pharmaceuticals for weight loss
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dietary, semaglutide or/and metformin
patients were prescribed dietary and pharmaceuticals for weight loss
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* patients followed-up less than 1 times within 3 months;
* patients having incomplete data;
* patients changing their interventions during fol-low-ups
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Second Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-1042
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.